Touchlight opens its new manufacturing facility in a newly-renovated Victorian-era building. (Credit: Touchlight)

May 25, 2023 12:29 PM EDT

DNA manufacturer Touchlight expands its campus to Victorian-era waterworks building

Tyler Patchen

News Reporter

The manufacturing spaces for any type of DNA work may bring up images of a large, windowless, warehouse-type building, or a more modern facade donned …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

DNA manufacturer Touchlight expands its campus to Victorian-era waterworks building

Tyler Patchen

News Reporter

Sign up to read this article for free.

RFK Jr. and Elon Musk want to ban pharma ads. They wouldn't be the first to try

Jazz wins approval for bispecific in biliary tract cancer

Novartis seeks more bolt-on deals as it purchases neuro startup for up to $1.1B

At Jefferies, all that manufacturers want to talk about is GLP-1s

FDA adcomm raises risk questions on AstraZeneca’s Andexxa

Are programs with compounded GLP-1s safe for your population?

DNA man­u­fac­tur­er Touch­light ex­pands its cam­pus to Vic­to­ri­an-era wa­ter­works build­ing

Tyler Patchen

News Reporter

Sign up to read this article for free.

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

DNA manufacturer Touchlight expands its campus to Victorian-era waterworks building

RFK Jr. and Elon Musk want to ban pharma ads. They wouldn't be the first to try

Jazz wins approval for bispecific in biliary tract cancer

Novartis seeks more bolt-on deals as it purchases neuro startup for up to $1.1B

At Jefferies, all that manufacturers want to talk about is GLP-1s

FDA adcomm raises risk questions on AstraZeneca’s Andexxa

Are programs with compounded GLP-1s safe for your population?